• OncologyTube
    • 0
      • Title
        User LIVE NOW
      • LIVE NOW
        Title
        User
        • Sign In
    • Home
    • Trending

    • Sign In

    • Audios and Videos
    • Videos
    • Audios

    • Channels

    • Browse Channels

    • Categories

    • Acute Lymphoblastic Leukemia 5636
    • Acute Myelogenous Leukemia 148
    • Bladder Cancer 49
    • Bone Metastases 1
    • Brain Cancer 16
    • Breast Cancer 120
    • Business Management 2
    • Cervical Cancer 2
    • Chronic Lymphocytic Leukemia 148
    • Chronic Myelogenous Leukemia 16
    • Colorectal Cancer 75
    • Gastrointestinal Cancer 70
    • General 244
    • Head and Neck Cancers 34
    • Hematologic Malignancies 79
    • Hodgkin Lymphoma 18
    • Immunotherapy 83
    • Kidney Cancer 364
    • Liver Cancer 11
    • Lymphoma 145
    • Melanoma and Skin Cancer 51
    • Multiple Myeloma 333
    • Myeloproliferative Disease 15
    • News 115
    • Non-Hodgkin Lymphoma 44
    • Non-Small Cell Lung Cancer 267
    • Other 110
    • Ovarian Cancer 10
    • Pancreatic Cancer 54
    • Patient Resources 27
    • Prostate Cancer 148
    • Small Cell Lung Cancer 58
    • Soft Tissue Sarcoma 9
    • Supportive Care 38
    • Testicular Cancer 2
    • Urology 6
    • Uterine Cancer 2

    • About
    • Contact
    Algorithm Personalizing Best Targets for Immunotherapy Algorithm Personalizing Best Targets for Immunotherapy
    0:07:37

    Algorithm Personalizing Best Targets for Immunotherapy

    Lee P. Richman, MD, Andrew J. Rech, MD and Robert H. Vonderheide, MD of @PennMedicine discuss an algorithm personalizes which cancer mutations are best for immunotherapy.

    ____________

    When tumor cells expand, tens of thousands of genetic mutations are often spawned. It's like finding a few needles in a haystack to figure out which ones are most important to try with immunotherapy. Now a new model built by researchers at the University of Pennsylvania's Abramson Cancer Center hand-picks certain needles so they can be leveraged in more effective, personalized cancer vaccines. Cell Systems today published data on the design of the template, and the algorithm is already available online as a resource-serving open source software.

    “There are mutations in tumors that can lead to powerful immune responses, but for every one mutation that generates a robust response, about 50 mutations don’t work at all, which means the signal-to-noise ratio is not great,” said the study’s lead author Lee P. Richman, an MD/PhD candidate in Cancer Biology in the Perelman School of Medicine at the University of Pennsylvania. “Our model works like a filter that highlights the signal and shows us which targets to focus on.”

    Actually, the sequencing of a tumor and the detection of potential immunotherapies is based on a calculation called the burden of tumor mutations (TMB), essentially a measure of the frequency of mutations in a given tumor. Tumors with high mutation rates are more likely to respond to inhibitors such as PD-1 targeted immunotherapy. The problem is that as cancer cells divide, they mutate at random, and the possible mutations are almost infinite as they multiply exponentially. This means that while a given immunotherapy may target a certain percentage of cancer cells, it may not be sufficient for any particular patient to be an effective treatment.

    Alternatively, the design of the Penn team looks at protein sequences from individual patient samples and determines how much of it looks similar to healthy cells and how much looks different enough to respond to it by the immune system. The more dissimilar it is, the stronger it serves for immunotherapy because it is more likely to attract and activate therapies of healthy cells with less collateral damage. The estimation of the model is also tailored to the test of each person. The group analyzed samples of 318 patients from five different data sets of clinical trials and not only verified the correlation between dissimilarity and promise as a target for immunotherapy, but also noticed that dissimilarity in patients with non-small cell lung cancer associated with increased overall survival after PD-1 therapy.

    With so many different possibilities of mutations, we essentially boiled the question of which targets to use down to a math problem, then developed an algorithm to solve it,” said Andrew J. Rech, MD, PhD, a resident in Pathology and Laboratory Medicine and the study’s co-senior author along with Robert H. Vonderheide, MD, DPhil, director of the Abramson Cancer Center. “We also knew it was important to make this model available for other researchers to help inform vaccine development and clinical trials.”

    Future work will also include applying the technique to more data sets to expand the algorithm as well as its use in trials, the researchers say.

    Immunotherapy
    35 Views
    1 month ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login

    Live

    Trending

    Annual Meeting 2015: Improved Cancer Treatments Linked to Reduced Late Mortality in Childhood Cancer Survivors
    00:04:49

    Annual Meeting 2015: Improved Cancer Treatments Linked to Reduced Late Mortality in Childhood Cancer Survivors

    Acute Lymphoblastic Leukemia
    844 Views
    4 years ago
    EMJ
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    M7824 Immuno-oncology Drug Study Data
    00:02:48

    M7824 Immuno-oncology Drug Study Data

    Gastrointestinal Cancer
    95 Views
    1 year ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    The challenges facing elderly AML treatment
    00:01:45

    The challenges facing elderly AML treatment

    Acute Lymphoblastic Leukemia
    179 Views
    2 years ago
    VJHemOnc
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Phase 1b trial of durvalumab plus tremelimumab for advanced non-small cell lung cancer
    00:03:15

    Phase 1b trial of durvalumab plus tremelimumab for advanced non-small cell lung cancer

    Acute Lymphoblastic Leukemia
    258 Views
    3 years ago
    EMJ
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    IMWG Conference Series:  MRD testing/response criteria
    00:13:02

    IMWG Conference Series: MRD testing/response criteria

    Acute Lymphoblastic Leukemia
    469 Views
    4 years ago
    InternationalMyelomaFoundation
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    A Unified Approach to Higher Risk MDS: Standard and Emerging Therapies
    00:22:07

    A Unified Approach to Higher Risk MDS: Standard and Emerging Therapies

    Acute Lymphoblastic Leukemia
    670 Views
    3 years ago
    imedex
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Results and impact of TAILORx: Trial Assigning IndividuaLized Options for Treatment (Rx) | Dr André Robidoux at ECC 2015
    00:04:38

    Results and impact of TAILORx: Trial Assigning IndividuaLized Options for Treatment (Rx) | Dr André Robidoux at ECC 2015

    Acute Lymphoblastic Leukemia
    650 Views
    4 years ago
    EMJ
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Adverse effects of immune checkpoint inhibitors
    00:02:57

    Adverse effects of immune checkpoint inhibitors

    Acute Lymphoblastic Leukemia
    950 Views
    3 years ago
    VJOncology
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Novel therapeutic options for Waldenström’s macroglobulinemia
    00:02:35

    Novel therapeutic options for Waldenström’s macroglobulinemia

    Non-Hodgkin Lymphoma
    76 Views
    1 year ago
    VJHemOnc
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    KEYNOTE-189: Clinical Implications in Patients with Advanced Non-Squamous NSCLC and Low (1-49%) Tumor PD-L1 Expression (BMIC-032)
    00:06:15

    KEYNOTE-189: Clinical Implications in Patients with Advanced Non-Squamous NSCLC and Low (1-49%) Tumor PD-L1 Expression (BMIC-032)

    Acute Lymphoblastic Leukemia
    371 Views
    1 year ago
    BeaconMedIC
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Carboplatin + Paclitaxel + HPV Vaccine Shows Dramatic Response
    00:01:56

    Carboplatin + Paclitaxel + HPV Vaccine Shows Dramatic Response

    Acute Lymphoblastic Leukemia
    954 Views
    2 years ago
    AnnualMeeting-SITC2017
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Presentation Overview: Mutational Landscapes of African American Colon Cancers
    00:04:38

    Presentation Overview: Mutational Landscapes of African American Colon Cancers

    Acute Lymphoblastic Leukemia
    1,960 Views
    2 years ago
    aacr2017
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login

    Latest Videos

    INNATE PHARMA HIGHLIGHTS FDA-APPROVED LUMOXITI® AT ASH 2019

    INNATE PHARMA HIGHLIGHTS FDA-APPROVED LUMOXITI® AT ASH 2019

    Acute Lymphoblastic Leukemia
    1 Views
    32 minutes ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refrac...

    New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refrac...

    Chronic Lymphocytic Leukemia
    1 Views
    35 minutes ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma

    Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma

    Non-Hodgkin Lymphoma
    2 Views
    36 minutes ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    First Clinical Data with MGTA-145 Show Single-Day Dosing and Collection of Robust Numbers of High-Quality Stem Cells in Healthy Volunteers

    First Clinical Data with MGTA-145 Show Single-Day Dosing and Collection of Robust Numbers of High-Quality Stem Cells in Healthy Volunteers

    News
    1 Views
    39 minutes ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Oncopeptides presents updated efficacy and safety data from pivotal Phase 2 HORIZON study in patients with RRMM at ASH Annual Meeting 2019

    Oncopeptides presents updated efficacy and safety data from pivotal Phase 2 HORIZON study in patients with RRMM at ASH Annual Meeting 2019

    News
    6 Views
    40 minutes ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis

    Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis

    Multiple Myeloma
    1 Views
    44 minutes ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login

    Acute Lymphoblastic Leukemia

    INNATE PHARMA HIGHLIGHTS FDA-APPROVED LUMOXITI® AT ASH 2019

    INNATE PHARMA HIGHLIGHTS FDA-APPROVED LUMOXITI® AT ASH 2019

    1 Views
    32 minutes ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Phase 1/2 AUGMENT-101 Trial @sloan_kettering Phase 1/2 AUGMENT-101 Trial @sloan_kettering
    0:04:52

    Phase 1/2 AUGMENT-101 Trial @sloan_kettering

    12 Views
    2 weeks ago
    Memorial Sloan Kettering
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Melanoma Rates Decline Found in Younger Population Melanoma Rates Decline Found in Younger Population
    0:03:21

    Melanoma Rates Decline Found in Younger Population

    2 Views
    3 weeks ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias

    Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias

    12 Views
    1 month ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    What is PFS2 in Advanced NSCLC, and Should we Care_ Unique Analysis of the KEYNOTE-024 trial [720p] - OncologyTube
    EE:EE:EE

    What is PFS2 in Advanced NSCLC, and Should we Care_ Unique Analysis of the KEYNOTE-024 trial [720p] - OncologyTube

    38 Views
    2 months ago
    Stan
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Patient Priorities Should be Paramount when Measuring Quality in Cancer Care According to Panelists at NCCN Policy Summit

    Patient Priorities Should be Paramount when Measuring Quality in Cancer Care According to Panelists at NCCN Policy Summit

    22 Views
    2 months ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login

    Acute Myelogenous Leukemia

    Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia

    Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia

    5 Views
    5 days ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment

    Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment

    15 Views
    1 month ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    How to Manage MDS Patients who are Ineligible for Transplant
    00:01:47

    How to Manage MDS Patients who are Ineligible for Transplant

    300 Views
    5 months ago
    obr
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    The Recent Wave of Approval in AML
    00:01:54

    The Recent Wave of Approval in AML

    138 Views
    5 months ago
    obr
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Updated Data on Gilteritinib in AML
    00:01:12

    Updated Data on Gilteritinib in AML

    16 Views
    5 months ago
    obr
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Latest Data on Uproleselan with Chemotherapy
    00:01:16

    Latest Data on Uproleselan with Chemotherapy

    100 Views
    5 months ago
    obr
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login

    Bladder Cancer

    EV-103: Enfortumab Vedotin plus Pembrolizumab #ESMO19 EV-103: Enfortumab Vedotin plus Pembrolizumab #ESMO19
    0:02:13

    EV-103: Enfortumab Vedotin plus Pembrolizumab #ESMO19

    17 Views
    1 month ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    EV-103 Phase I Trial Presented at #ESMO19 EV-103 Phase I Trial Presented at #ESMO19
    0:01:45

    EV-103 Phase I Trial Presented at #ESMO19

    24 Views
    1 month ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Seattle Genetics and Astellas Announce US FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer

    Seattle Genetics and Astellas Announce US FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer

    33 Views
    2 months ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Mount Sinai Receives $1.7 million to Study Natural Killer Cell Dysfunction in Bladder Cancer

    Mount Sinai Receives $1.7 million to Study Natural Killer Cell Dysfunction in Bladder Cancer

    23 Views
    2 months ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Strategies for Treating 2nd Line RCC Patients
    00:01:17

    Strategies for Treating 2nd Line RCC Patients

    54 Views
    5 months ago
    obr
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Treating Newly Diagnosed RCC Patients
    00:02:08

    Treating Newly Diagnosed RCC Patients

    53 Views
    5 months ago
    obr
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login

    Bone Metastases

    If Practitioner Identifies Light-Chain Amyloidosis | Referring to Site Where Trial is Open is a Great Idea
    00:00:40

    If Practitioner Identifies Light-Chain Amyloidosis | Referring to Site Where Trial is Open is a Great Idea

    194 Views
    1 year ago
    Annual-Meeting
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login

    Brain Cancer

    Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published

    Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published

    4 Views
    2 weeks ago
    alexvarney
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Predicting Tumor Recurrence: How Does This Help Us? Predicting Tumor Recurrence: How Does This Help Us?
    0:03:05

    Predicting Tumor Recurrence: How Does This Help Us?

    7 Views
    1 month ago
    Baylor College of Medicine
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Predicting Tumor Recurrence Predicting Tumor Recurrence
    0:03:36

    Predicting Tumor Recurrence

    20 Views
    1 month ago
    Baylor College of Medicine
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    How does this affect clinicians today? How does this affect clinicians today?
    0:01:20

    How does this affect clinicians today?

    7 Views
    2 months ago
    Cleveland Clinic
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Targeting Metabolic Reprogramming to Radiosensitize Glioblastoma Stem Cells Targeting Metabolic Reprogramming to Radiosensitize Glioblastoma Stem Cells
    0:01:26

    Targeting Metabolic Reprogramming to Radiosensitize Glioblastoma Stem Cells

    15 Views
    2 months ago
    Cleveland Clinic
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Oncoceutics Commemorates National Childhood Cancer Awareness Month

    Oncoceutics Commemorates National Childhood Cancer Awareness Month

    14 Views
    2 months ago
    alexvarney
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login

    Breast Cancer

    CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial

    CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial

    6 Views
    5 days ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Is This Going To Affect Survival? @DukeCancer @DrLolaFayanju Is This Going To Affect Survival? @DukeCancer @DrLolaFayanju
    0:03:14

    Is This Going To Affect Survival? @DukeCancer @DrLolaFayanju

    2 Views
    1 week ago
    Duke Cancer
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Radiation After Breast Cancer Diagnosis @DukeCancer @DrLolaFayanju Radiation After Breast Cancer Diagnosis @DukeCancer @DrLolaFayanju
    0:02:49

    Radiation After Breast Cancer Diagnosis @DukeCancer @DrLolaFayanju

    4 Views
    1 week ago
    Duke Cancer
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Who is Eligible for the AVIATOR Study? @SeattleCCA Who is Eligible for the AVIATOR Study? @SeattleCCA
    0:02:08

    Who is Eligible for the AVIATOR Study? @SeattleCCA

    2 Views
    3 weeks ago
    SeattleCCA
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    The AVIATOR Study @SeattleCCA The AVIATOR Study @SeattleCCA
    0:04:33

    The AVIATOR Study @SeattleCCA

    3 Views
    3 weeks ago
    SeattleCCA
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Roswell Park Breast Surgery Chief Gives Keynote Talk on Immunotherapy for Breast Cancer

    Roswell Park Breast Surgery Chief Gives Keynote Talk on Immunotherapy for Breast Cancer

    8 Views
    1 month ago
    Roswell Park
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login

    Business Management

    Two Sided Payment Agreements & The Risks Involved
    00:01:47

    Two Sided Payment Agreements & The Risks Involved

    116 Views
    11 months ago
    obr
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    MOASC COAnalyzer Tool Ricky Newton
    01:01:00

    MOASC COAnalyzer Tool Ricky Newton

    99 Views
    1 year ago
    moasc
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login

    Cervical Cancer

    Novel revelations in CLL biology with venetoclax/ibrutinib
    00:02:24

    Novel revelations in CLL biology with venetoclax/ibrutinib

    93 Views
    1 year ago
    VJHemOnc
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Immunotherapy in gynecological cancers: current and future landscape
    00:02:35

    Immunotherapy in gynecological cancers: current and future landscape

    474 Views
    1 year ago
    VJOncology
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login

    Chronic Lymphocytic Leukemia

    New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refrac...

    New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refrac...

    1 Views
    35 minutes ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login